Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.
OBJECTIVE
To assess the impact of highly active antiretroviral therapy, including a protease inhibitor (HAART/PI), on maternal glucose tolerance and fetal growth.


METHODS
A retrospective chart review of pregnancy outcomes of human immunodeficiency virus-infected pregnant women receiving HAART/PI (n=41) or zidovudine monotherapy (n=23).


RESULTS
Abnormal 1-hour glucose tolerance tests (1hGTT) were observed in 30% of subjects receiving HAART/PI between 24 and 28 weeks' gestation. An elevated 1hGTT was associated with a significantly lower mean birth weight in subjects receiving HAART/PI compared to babies born to mothers with a normal 1hGTT (3.40+/-0.09 vs 3.00+/-0.18 kg, p<0.05, ANOVA).


CONCLUSIONS
HAART/PI therapy is associated with an increased rate of impaired glucose tolerance in pregnancy and impaired fetal growth. This finding merits further investigation.
Chmait
Ramen
R
Department of Reproductive Medicine, University of California San Diego, La Jolla, CA, USA.
Franklin
Patricia
P
Spector
Stephen A
SA
Hull
Andrew D
AD
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001724:Birth Weight; D001786:Blood Glucose / Q000032:analysis*; D005260:Female; D005951:Glucose Tolerance Test; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000503:physiopathology*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies
D001786:Blood Glucose; D011480:Protease Inhibitors